Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Consolidated Edison, Inc. (ED) vs Inovio Pharmaceuticals Inc (INO) Price & Performance

Consolidated Edison, Inc.Trade
Inovio Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

Consolidated Edison, Inc. vs Inovio Pharmaceuticals Inc — how do they compare? Consolidated Edison, Inc. trades at $107.41 (market cap $39.76B), while Inovio Pharmaceuticals Inc trades at $0.77 (market cap $78.55M). The key difference: Consolidated Edison, Inc. is far larger — about 506.2× Inovio Pharmaceuticals Inc's market cap, and Consolidated Edison, Inc. pays a 3.27% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.

EDINO
Market Cap
$39.76B$78.55M
Sector
UtilitiesHealth
52-Week High
$115.46$2.87
52-Week Low
$95.37$0.66
Enterprise Value
$66.61B$49.56M
Dividend Yield
3.27%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Consolidated Edison, Inc.

Consolidated Edison (ED) trades at $107.33, up 0.97% on the day, slightly above the consensus price target of $103.25. The stock shows a mixed technical picture with bearish moving averages but neutral oscillators, while fundamentals are stable with a P/E of 17.68, net income margin of 12.53%, and consistent dividends. Recent Q2 2026 earnings beat estimates with EPS of $0.83 versus $0.756 expected, though Q1 2026 missed expectations.

Outlook is cautious due to analyst sentiment favoring Hold (62.96%) and bearish technical signals, but the utility's regulated operations and mid-8% rate base growth support steady returns. Risks include high debt levels and interest rate sensitivity, while opportunities lie in grid upgrades for AI-driven power demand. The stock offers a defensive profile with a reliable dividend yield.

Inovio Pharmaceuticals Inc

INO trades at $0.76, up 2.74% today, but remains in a bearish technical trend. The company shows minimal revenue of $65K against high operating losses, with a net income margin of -130,000%. Recent quarterly EPS has beaten expectations. Analyst consensus is bullish with a $3.25 price target, but the stock faces significant fundamental challenges including negative cash flow and high valuation multiples.

The outlook hinges on FDA approval of INO-3107 in October 2026, a binary event that could drive substantial upside. However, persistent cash burn, negative profitability, and ongoing shareholder litigation present high risks. Investors should weigh the potential catalyst against the company's weak financial health and operational execution challenges.

Returns comparison

Trailing returns across standard periods

About Consolidated Edison, Inc.

Con Ed is a holding company for Consolidated Edison of New York, or CECONY, and Orange & Rockland, or O&R. These utilities provide steam, natural gas, and electricity to customers in southeastern New York—including New York City—and small parts of New Jersey. The two utilities will generate nearly all of Con Ed's earnings once it closes the sale of its clean energy business to RWE. Con Ed's clean energy business owns the second-largest portfolio of utility-scale solar projects in the U.S. Following the sale, Con Ed's only non-utility earnings will come from investments in gas and electric transmission.

Read more on ED

About Inovio Pharmaceuticals Inc

Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.

Read more on INO